Results 31 to 40 of about 1,009 (151)

t(8;14)(q24;q32) in BPDCN [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019
Review on t(8;14)(q24;q32) in BPDCN, with data on ...
openaire   +2 more sources

Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Clinical Case Reports, 2021
BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.
Ken Sagou, Makoto Ito, Yuma Kawamura, Shun Ukai, Miyo Goto, Nobuaki Fukushima, Kazutaka Ozeki, Ryuichi Fukuyama, Akio Kohno   +8 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018
Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved.
openaire   +2 more sources

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer

Case Reports in Hematology, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells.
Jiankun Tong, Sergei Aksenov, Beth M. Siegel, Lihong Wei, William H. Rodgers   +4 more
doaj   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. [PDF]

Blood Neoplasia
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA.   +9 more
europepmc   +3 more sources

A case report on BPDCN: Blastic Plasmacytoid Dendritic Cell Neoplasm

World Journal of Advanced Research and Reviews, 2023
Dendritic cells are present in both lymphoid and non-lymphoid organs, which are heterogenous group of nonphagocytic and nonlymphoid immune accessory cells. Plasmacytoid dendritic cell (which has an eccentric nuclei) are subset of dendritic cells aid in secreting high levels of type 1 interferons by activation and gaining dendritic cell like morphology,
Mercy Paul M, Sukumar Naidu KD
openaire   +1 more source

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN

Biology of Blood and Marrow Transplantation, 2020
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. It commonly presents as skin lesions with or without bone marrow, lymph node or systemic involvement. Limited retrospective data have shown durable remissions after allogeneic (allo) hematopoietic cell
Muzaffar H. Qazilbash, Jeremy Ramdial, Qaiser Bashir, Denai R Milton, Romil D. Patel, Uday R. Popat, Chitra M. Hosing, Partow Kebriaei, Amin M. Alousi, Stefan O. Ciurea, Marina Konopleva, Richard E. Champlin, Naveen Pemmaraju   +12 more
openaire   +1 more source

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report

eJHaem, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Jad Sibai, RuiQi Chen, Ibrahim Al Nabhani, Maria Agustina Perusini, Hassan Sibai   +4 more
doaj   +1 more source

Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

HemaSphere, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with overall survival.
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi   +10 more
doaj   +1 more source

Targeted diphtheria toxin to treat BPDCN

Blood, 2014
In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
openaire   +3 more sources